Literature DB >> 33883536

Efficacy and safety of pharmacological, physical, and psychological interventions for the management of chronic pain in children: a WHO systematic review and meta-analysis.

Emma Fisher1,2, Gemma Villanueva3, Nicholas Henschke3, Sarah J Nevitt4, William Zempsky5, Katrin Probyn3, Brian Buckley3, Tess E Cooper6,7, Navil Sethna8,9, Christopher Eccleston1,2,10.   

Abstract

ABSTRACT: Chronic pain in childhood is an international public health problem. We conducted a systematic review and meta-analysis to provide a summary of the published evidence of pharmacological, physical, and psychological therapies for children with chronic pain conditions. We searched CENTRAL, MEDLINE, EMBASE, and PsycINFO from inception to April 2020; clinical trial registries; and other sources for randomised controlled trials or comparative observational trials. We extracted critical outcomes of pain intensity, quality of life, physical functioning, role functioning, emotional functioning, sleep, and adverse events. We assessed studies for risk of bias and certainty of the evidence using GRADE. We included 34 pharmacological (4091 participants), 25 physical therapy (1470 participants), and 63 psychological trials (5025 participants). Participants reported a range of chronic pain conditions. Most studies were assessed to have unclear or high risk of bias across multiple domains. Pharmacological, physical, and psychological therapies showed some benefit for reducing pain, posttreatment, but only physical and psychological therapies improved physical functioning. We found no benefit of any treatment modality for health-related quality of life, role functioning, emotional functioning, or sleep. Adverse events were poorly reported, particularly for psychological and physical interventions. The largest evidence base for the management of chronic pain in children supports the use of psychological therapies, followed by pharmacological and physical therapies. However, we rated most outcomes as low or very low certainty, meaning further evidence is likely to change our confidence in the estimates of effects. This protocol was registered on PROSPERO (CRD42020172451).
Copyright © 2021 International Association for the Study of Pain.

Entities:  

Mesh:

Year:  2022        PMID: 33883536     DOI: 10.1097/j.pain.0000000000002297

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  5 in total

Review 1.  Outpatient Approach to Resistant and Refractory Migraine in Children and Adolescents: a Narrative Review.

Authors:  Alison Marshall; Rebecca Lindsay; Michelle A Clementi; Amy A Gelfand; Serena L Orr
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-26       Impact factor: 6.030

2.  Mechanism-Based Pharmacological Treatment for Chronic Non-cancer Pain in Adolescents: Current Approaches and Future Directions.

Authors:  Alice Bruneau; Sabrina Carrié; Lorenzo Moscaritolo; Pablo Ingelmo
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

3.  Assessing knowledge, attitude and practice of community pharmacists on the pain management and implications in UAE children.

Authors:  Ammar Abdulrahman Jairoun; Sabaa Saleh Al-Hemyari; Moyad Shahwan; Maimona Jairoun; Amanj Kurdi; Brian Godman
Journal:  Pharm Pract (Granada)       Date:  2022-05-03

4.  Phenotyping Chronic Musculoskeletal Pain in Male and Female Adolescents: Psychosocial Profiles, Somatosensory Profiles and Pain Modulatory Profiles.

Authors:  Don Daniel Ocay; Cynthia L Larche; Natalie Betinjane; Alexandre Jolicoeur; Marie Josee Beaulieu; Neil Saran; Jean A Ouellet; Pablo M Ingelmo; Catherine E Ferland
Journal:  J Pain Res       Date:  2022-02-26       Impact factor: 3.133

5.  A prospective, double-blind, pilot, randomized, controlled trial of an "embodied" virtual reality intervention for adults with low back pain.

Authors:  Christopher Eccleston; Emma Fisher; Sammeli Liikkanen; Toni Sarapohja; Carina Stenfors; Satu K Jääskeläinen; Andrew S C Rice; Leena Mattila; Taru Blom; J Raymond Bratty
Journal:  Pain       Date:  2022-03-25       Impact factor: 7.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.